System and method for treating ischemia by improving cardiac efficiency

• US 7,908,003 B1
• Filed: 06/15/2007
• Issued: 03/15/2011
• Est. Priority Date: 08/19/1996
• Status: Expired due to Fees

• Current Assignee: MR3 Medical, LLC
• Original Assignee: MR3 Medical, LLC
• Inventors: Mower, Morton M.
• Primary Examiner(s): Getzow; Scott M
• Application Number:
  US11/763,768
• Time in Patent Office: 1,369 Days
• Field of Search: 607 4- 28
• US Class Current: 607/9
• CPC Class Codes: A61B 5/349 Detecting specific parameters of the electrocardiograph cycle
• CPC Class Codes: A61B 5/358 Detecting ST segments
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
• CPC Class Codes: A61N 1/365 controlled by a physiological parameter, e.g. heart potential evoked response A61N1/371
• CPC Class Codes: A61N 1/36557 controlled by chemical substances in blood

Abstract

A system and method for treating ischemic heart disease by increasing heart efficiency. By application of an anodal pulse at or above threshold, the efficiency of the heart is improved by increasing the resting membrane potential of the myocardial cells, increasing the size of the anodal virtual stimulatory electrode, or reducing the ventricular stretching during filling of the ventricle.

Claims

1. A cardiac stimulator comprising:

a cardiac sensor, wherein the cardiac sensor senses a measure of heart function and wherein the cardiac sensor produces an output signal indicative of the heart function measure;

a processor, wherein the processor comprises instructions for producing a first alert signal if the heart function measure is indicative of ischemia;

a waveform generator, wherein the waveform generator produces a stimulation signal in response to the first alert signal and wherein the stimulation signal comprises a leading anodal phase and a trailing phase cathodal phase that is produced after two or more leading anodal phases and wherein the trailing phase follows a preceding leading anodal phase after a delay of from 0 to about 0.25 milliseconds;

and

an electrode for applying the stimulation signal to the cardiac tissue.

2. The cardiac stimulator of claim 1, wherein the measure indicative of ischemia is selected from the group consisting of an ST segment depression on a ventricular sensing (pacing) lead, a pH change, and a lactate buildup.

3. The cardiac stimulator of claim 1, wherein the leading anodal phase amplitude is about 3-20 volts.

4. The cardiac stimulator of claim 1, wherein the leading anodal phase width is about 0.1 milliseconds to 0.7 milliseconds.

5. The cardiac stimulator of claim 1, wherein the trailing phase is a cathodal phase that follows the leading anodal phase after a delay of from 0 to about 0.25 milliseconds.

6. The cardiac stimulator of claim 1,

wherein the processor further comprises instructions for:

detecting a preset number of heartbeats; and

issuing a second alert signal when the preset number of heartbeats is reached,

wherein the trailing phase is a cathodal phase produced in response to the second alert signal.

7. The cardiac stimulator of claim 1 further comprising a user interface, wherein the user interface comprises instructions for:

accepting a demand signal from a user of the cardiac stimulator; and

sending the demand signal to the processor, and

wherein the processor further comprises instructions for producing the first alert signal from the demand signal.

8. A cardiac stimulator comprising:

a cardiac sensor, wherein the cardiac sensor senses a measure of heart function and wherein the cardiac sensor produces an output signal indicative of the heart function measure;

a processor, wherein the processor comprises instructions for producing a first alert signal if the heart function measure is indicative of ischemia;

a waveform generator, wherein the waveform generator produces a stimulation signal solely comprising an anodal waveform in response to the first alert signal and wherein the stimulation signal has an amplitude and a duration; and

an electrode for applying the stimulation signal to the cardiac tissue.

9. The cardiac stimulator of claim 8, wherein the measure indicative of ischemia is selected from the group consisting of an ST segment depression on a ventricular sensing (pacing) lead, a pH change, and a lactate buildup.

10. The cardiac stimulator of claim 8, wherein the amplitude is about 3-20 volts.

11. The cardiac stimulator of claim 8, wherein the duration is about 0.1 milliseconds to 0.7 milliseconds.